SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " KGaA " 19 found 🔀 AI-powered Shuffle
Merck business unit opens R&D facility in Sheboygan Falls
EMD Electronics, the North America electronics business unit of Germany-based global health care and biopharmaceutical company Merck KGaA, today announced
Financial Results Press Conference: BVB in excellent financial health
As previously forecast in February 2026, the Borussia Dortmund GmbH & Co. KGaA Group reported an annual net loss of EUR 21.7 million for the past fiscal year. This is primarily due to the early elimin...
Health Care Roundup: Market Talk
Find insight on Moderna, Novonesis, Merck KGaA and more in the latest Market Talks covering the health care sector.
Merck KGaA raises profit guidance on momentum in Life Science, Electronics units
Germany's Merck KGaA lifted its earnings guidance range for 2026 on Thursday, citing a further gain in demand for its drug manufacturing supplies and semiconductor materials, while posting better-than-expected quarterly results.
Merck Lifts Guidance on Life Science, Electronics
Merck KGaA lifted its full-year earnings and sales outlook thanks to a stronger performance in its lab equipment and electronics businesses.
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce Biotech has learned. The trial, which began only back in April, was a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score following treatment with SAR445399 compared with placebo in adults aged 18 to 80 years with NCFB, a chronic lung disease. The trial was officially reported as halted on July 29, the day before Sanofi’s second-quarter earnings call. The decision to pause the trial was made “as part of a company-wide portfolio review for strategic business reasons,” and not due to safety concerns, a Sanofi spokesperson told Fierce. The move to pause the NCFB trial comes during a trying time for Sanofi following a year filled with a series of trial fails. In February, the French pharma ousted CEO Paul Hudson and appointed Merck KGaA leader Belén Garijo, M.D., Ph.D., to steer the ship. Since then, Garijo has been doing a deep dive on correcting the company’s strewn R&D and clinical strategies. On July 24, Sanofi scrapped amlitelimab for atopic dermatitis, despite its lore as being a potential $5 billion blockbuster. During its second-quarter report, the company abandoned two more assets, balinatunfib and itepekimab, following failed trial results in psoriasis and chronic obstructive pulmonary disease, respectively. SAR445399, only first revealed by Sanofi in 2023, is an anti-interleukin-1 receptor 3 monoclonal antibody developed to block the interleukin 1, 33, and 36 cytokine pathways. These pathways can be important in chronic immune-related dermatologic diseases, such as atopic dermatitis and hidradenitis suppurativa, as well as respiratory conditions, such as NCFB. Related Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues NCFB affects roughly half a million people in the U.S., with a global incidence of greater than one million cases. In August 2025, Insmed received FDA approval for Brinsupri, a DPP1 inhibitor targeting neutrophil activation, for treatment of NCFB in adults and kids ages 12 and older. The British biotech Infex Therapeutics showed promising NCFB phase 2a data using their monoclonal antibody, INFEX702, which acts by disabling Pseudomonas aeruginosa, a bacteria known to be a major pathogen of NCFB. Sanofi is currently running a separate phase 2 study testing SAR445399 as a potential treatment for the inflammatory skin condition hidradenitis suppurativa.
Merck KGaA to Acquire Bio-Techne for $11.3B, Expanding Life Science Tools Presence
Merck KGaA, Darmstadt, Germany, has agreed to acquire Bio-Techne for approximately $11.3 billion, the companies said today, in a deal designed to position the buyer as more of a leader across the life science value chain by expanding its presence in high-growth, next-generation life-sci markets with Bio-Techne’s tools, analytical technologies, and consumables.
Merck KGaA bolsters life sciences business with $11.3B Bio-Techne buy
The deal comes a matter of weeks after Kai Beckmann was promoted to CEO at Merck and signalled his intent to broaden the company's scope for M&A.
Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion
The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist.
Germany's Merck to buy Bio-Techne for $11.3 billion
Merck KGaA has agreed to acquire biotech firm Bio-Techne for $11.3 billion, the German science and healthcare firm said in a statement on Thursday.
Germany's Merck to buy Bio-Techne for $73 per share
Merck KGaA has agreed to acquire biotech firm Bio-Techne Corp for $73 per share in cash, the German science and healthcare firm said in a statement on Thursday.
Germany’s Merck to Buy Bio-Techne for $11 Billion
Merck KGaA offered $73 a share in cash to buy Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier’s closing price Wednesday.
Shane Bowen a welcome addition to Patriots coaching staff
Bowen was hired as a defensive analyst in April.
Health Care Roundup: Market Talk
Find insight on Merck KGaA, IHH Healthcare and more in the latest Market Talks covering the health care sector.
Merck KGaA acquires JSR chromatography business
Merck KGaA has completed its previously announced acquisition of the chromatography business of JSR Life Sciences.
Mets’ latest roster cuts include Ronny Mauricio
Mauricio always kind of figured to start in Syracuse so long as Francisco Lindor returned on time.
Health Care Roundup: Market Talk
Find insight on Merck KGaA, Bayer and more in the latest Market Talks covering the health care sector.
Merck CEO on US Business, Life Sciences Innovation
Merck KGaA Chief Executive Officer Belen Garijo says the company will continue to collaborate with the US and deliver life sciences innovation to patients. She spoke to Bloomberg's Francine Lacqua on the sidelines of the 2026 World Economic Forum in Davos, Switzerland. (Source: Bloomberg)